181 related articles for article (PubMed ID: 17219151)
1. An MVA vaccine overcomes tolerance to human p53 in mice and humans.
Song GY; Gibson G; Haq W; Huang EC; Srivasta T; Hollstein M; Daftarian P; Wang Z; Diamond D; Ellenhorn JD
Cancer Immunol Immunother; 2007 Aug; 56(8):1193-205. PubMed ID: 17219151
[TBL] [Abstract][Full Text] [Related]
2. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
[TBL] [Abstract][Full Text] [Related]
3. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
[TBL] [Abstract][Full Text] [Related]
4. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.
Ishizaki H; Song GY; Srivastava T; Carroll KD; Shahabi V; Manuel ER; Diamond DJ; Ellenhorn JD
J Immunother; 2010; 33(6):609-17. PubMed ID: 20551836
[TBL] [Abstract][Full Text] [Related]
5. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
7. Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.
Song GY; Srivastava T; Ishizaki H; Lacey SF; Diamond DJ; Ellenhorn JD
Cancer Invest; 2011 Oct; 29(8):501-10. PubMed ID: 21843052
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
[TBL] [Abstract][Full Text] [Related]
10. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
[No Abstract] [Full Text] [Related]
11. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
[TBL] [Abstract][Full Text] [Related]
12. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.
Soong RS; Trieu J; Lee SY; He L; Tsai YC; Wu TC; Hung CF
PLoS One; 2013; 8(2):e56912. PubMed ID: 23457640
[TBL] [Abstract][Full Text] [Related]
13. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
16. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
[TBL] [Abstract][Full Text] [Related]
17. An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53.
Blaszczyk-Thurin M; Ertl IO; Ertl HC
Scand J Immunol; 2002 Oct; 56(4):361-75. PubMed ID: 12234257
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
[TBL] [Abstract][Full Text] [Related]
19. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
[TBL] [Abstract][Full Text] [Related]
20. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]